Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3854 | lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate Wiki | 0.71 |
drug2960 | Sample collection Wiki | 0.50 |
drug3690 | basic treatment Wiki | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.05 |
D007239 | Infection NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
The novel coronavirus infectious disease ( COVID-19") induced by novel coronavirus(SARS-CoV-2) in December 2019 has outbreaked in Wuhan. It may lead to epidemic risk in global. As the COVID-19 is an emerging infectious disease, it has not scientifically recognized and has no effective drugs for treatment currently. Therefore, we will launch a scientific project "The efficacy and safety of carrimycin treatment in 520 patients with COVID-19 stratificated clinically: A multicenter, randomized (1:1), open-controlled (one of lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate) study" . We try to establish the criteria for clinical cure and the early predictive model of COVID-19 progression. The primary efficiency outcomes were:(1) Fever to normal time (day); (2) Pulmonary inflammation resolution time (HRCT) (day); and (3)Negative conversion (%) of SARS-CoV-2 RNA at the end of treatment. The secondary efficiency outcomes and adverse events were observed.
Description: Fever to normal time (day)
Measure: Fever to normal time (day) Time: 30 daysDescription: Pulmonary inflammation resolution time (HRCT) (day)
Measure: Pulmonary inflammation resolution time (HRCT) (day) Time: 30 daysDescription: Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment
Measure: Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment Time: 30 daysThis is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
Description: To evaluate the efficacy and safety of carrimycin compared to SOC in patients hospitalized with severe SARS-CoV-2 pneumonia.
Measure: Percentage of patients alive without need for supplemental oxygen and ongoing in patient-medical care (SOC treatment for COVID-19) at Day 28 Time: At Day 28Description: To evaluate efficacy of carrimycin administered for treatment of severe COVID-19 in hospitalized patients between patients receiving carrimycin vs placebo. Time to recovery is defined as time point when a patient reaches level 3 or lower on the 8-Category ordinal scale and does not return to a level > 3 during the 28-day period. The 8-Category ordinal scale score ranges from 1 to 8. Score 1: Not hospitalized, no limitations on activities; 2: Not hospitalized, limitation on activities, home oxygen requirement or both; 3: Hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care; 4: Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care; 5: Hospitalized, requiring supplemental oxygen; 6: Hospitalized, requiring noninvasive ventilation or high flow oxygen devices; 7: Hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation and score 8: Death. Higher scores indicate worse outcome.
Measure: Time to recovery Time: From screening Day (Day -2 to Day -1) until Day 28Description: To evaluate the efficacy of carrimycin administered for the treatment of severe COVID-19 in hospitalized patients between patients receiving carrimycin vs placebo. The 8-Category ordinal scale score ranges from 1 to 8. Score 1 indicates: Not hospitalized, no limitations on activities; 2: Not hospitalized, limitation on activities, home oxygen requirement or both; 3: Hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care; 4: Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care; 5: Hospitalized, requiring supplemental oxygen; 6: Hospitalized, requiring noninvasive ventilation or high flow oxygen devices; 7: Hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) and score 8 indicates: Death. Higher scores indicate worse outcome
Measure: Mean difference from baseline (Days -2 to -1) to Day 28 as per the 8 category ordinal scale Time: Screening Day (Day -2 to Day -1) until Day 28Description: To evaluate the efficacy of carrimycin administered for the treatment of severe COVID-19 in hospitalized patients between patients receiving carrimycin vs placebo. Radiological imaging (lung computed tomography scan and chest X-ray) will be used to determine change in lung imaging.
Measure: Change in lung imaging Time: Days 7, 14 and 28Description: To evaluate the efficacy of carrimycin administered for the treatment of severe COVID-19 in hospitalized patients between patients receiving carrimycin vs placebo. To evaluate the change in viral load between treatment arms and to evaluate the relationship between change in viral load over time with time to clinical recovery.
Measure: Negative conversion ratio of SARS-CoV-2 RNA in nasopharyngeal samples after treatment. Time: Days 3, 7 and 14Description: To evaluate the efficacy of carrimycin administered for the treatment of severe COVID-19 in hospitalized patients between patients receiving carrimycin vs placebo. The SOFA score ranges from 0 to 4. Lower score predicts better organ functioning and higher score represents severe organ failure.
Measure: Improvement in sequential organ failure assessment (SOFA) score Time: Days 3, 7, 10, 14 and 28 after treatmentDescription: To evaluate length of hospital stay and to evaluate time to successful discharge between patients receiving carrimycin vs placebo.
Measure: Length of hospital stay (in days) Time: From Screening Day (Day -2 to Day -1) until Day 60 or Early WithdrawalDescription: To evaluate mortality rates between patients receiving carrimycin vs placebo.
Measure: Number of patients with all cause mortality at Days 14 and 28 Time: From Screening Day (Day -2 to Day -1) until Day 60 or Early WithdrawalDescription: To evaluate the safety and tolerability of the carrimycin and to describe the safety profile of treatments as reflected by AEs and SAEs.
Measure: Number of patients with adverse event (AEs) and Serious adverse events (SAEs) Time: Day 28 and Day 60Description: To evaluate the safety and tolerability of the carrimycin and to describe the safety profile of treatments. The routine ECG will include heart rate, QTc interval, ST segment and T wave changes
Measure: Number of patients with changes in routine electrocardiogram (ECG) from Day 1 up to Day 14 Time: Day 1 until Day 14Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports